Skip to Content


In the US, Muromonab-CD3 (muromonab-cd3 systemic) is a member of the drug class selective immunosuppressants and is used to treat Rejection Prophylaxis and Rejection Reversal.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Therapeutic Categories

Selective immunosuppressant

Monoclonal antibody

Chemical Name

A biochemically purified IgG2α immunoglobulin consisting of a heavy chain of approx. 50.000 daltons and a light chain of approx. 25.000 daltons.

Foreign Names

  • Muromonabum-CD3 (Latin)
  • Muromonab-CD3 (German)
  • Muromonab-CD3 (French)
  • Muromonab-CD3 (Spanish)

Generic Names

  • Muromonab-CD3 (OS: DCF, USAN)
  • Anti-CD3 (IS)
  • Human T-cell inhibitor (IS)

Brand Names


DCFDénomination Commune Française
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.